Ascentage Pharma International : Resignation of Non-executive Director and Appointment of Independent Non-executive Director

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

ASCENTAGE PHARMA GROUP INTERNATIONAL

亞 盛 醫 藥 集 團

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6855)

RESIGNATION OF NON-EXECUTIVE DIRECTOR

AND

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

RESIGNATION OF NON-EXECUTIVE DIRECTOR

The board (the "Board") of directors (the "Directors") of Ascentage Pharma Group International (the "Company" or "Ascentage Pharma", together with its subsidiaries, the "Group") hereby announces that Mr. Zhao Qun ("Mr. Zhao") has tendered his resignation as a non-executive Director with effect from March 31, 2021 in order to devote more time for his fund investment business and other personal businesses.

Mr. Zhao has confirmed that he has no disagreement with the Board and the Company and there are no other matters in respect of his resignation which need to be brought to the attention of The Stock Exchange of Hong Kong Limited and the shareholders of the Company (the "Shareholders").

The Board would like to express its sincere appreciation to Mr. Zhao for his valuable contribution to the Company during the tenure of his service as non-executive Director.

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The Board is pleased to announce it has appointed Dr. David Sidransky ("Dr. Sidransky") as an additional independent non-executive Director with effect from March 31, 2021. As such, pursuant to the articles of association of the Company, Dr. Sidransky shall hold office until the first general meeting of the Company after his appointment, being the upcoming annual general meeting of the Company (the "AGM"), and be subject to re-election by the Shareholders at the AGM.

- 1 -

The biographical details of Dr. Sidransky are set out as follows:

Dr. David Sidransky, M.D., aged 60, currently serves as the director of the Head and Neck Cancer Research Division, professor in otolaryngology - head and neck surgery, professor in cellular and molecular medicine, and professor in urology and genetics of The Johns Hopkins University. Dr. Sidransky also currently serves as professor in oncology at the Johns Hopkins Oncology Center.

From 1984 to 1988, Dr. Sidransky attended the Baylor College of Medicine in the U.S. and earned his MD degree and then continued as an intern and resident in internal medicine, and chief resident in internal medicine until June 1988. Dr. Sidransky completed a fellowship in Oncology at The Johns Hopkins University and Hospital from July 1988 to June 1992 and was then appointed as faculty in July 1992.

Dr. Sidransky graduated with a Bachelor of Science degree in Chemistry from the Brandeis University in the U.S. in June 1981. Dr. Sidransky is a current member of the American Association of Cancer Research and the American Society of Clinical Oncology. He was a member of certain working groups under the National Cancer Institute, including the Development Diagnostics Working Group and the Cancer Prevention and Control Working Group. Dr. Sidransky has also received certifications from the American Board of Internal Medicine and the American Board of Medical Oncology.

In addition, Dr. Sidransky currently sits on the National Board of Scientific Advisors of the National Cancer Institute. He was a founder of Champions Oncology, Inc. (NASDAQ: CSBR) and currently Lead Board Director. He is on the Board of Directors of Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD), Orgenesis Inc. (NASDAQ: ORGS), and the Chairman of Advaxis, Inc. (NASDAQ: ADXS) and the Chairman of Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA). He is also Chairman of the MAB of the Flight Attendants Medical Research Foundation and the Adenocystic Carcinoma Research.

Dr. Sidransky has received numerous honors, such as the Israel Cancer Research Fund Osserman Award, the AACR-Richard and Hinda Rosenthal Foundation Award, the Toby Comet Award Bar Ilan University and the AACR Team Award Theme Circulating DNA. As of the date of this announcement, he is the author of over 550 articles published in professional journals, the author of 45 book chapters, reviews and commentaries, and the inventor of 28 patents.

Dr. Sidransky has entered into a letter of appointment with the Company for a term of service commencing on March 31, 2021 and ending on the date of the AGM. Dr. Sidransky will not receive any remuneration from the Company pursuant to this letter of appointment. Subject to the approval by the Shareholders of the re-election of Dr. Sidransky at the AGM, Dr. Sidransky will enter into a new letter of appointment with the Company for a term of three years commencing on the date of his re-election. Pursuant to this new letter

- 2 -

of appointment, Dr. Sidransky will receive remuneration per annum in the form of such number of restricted share units to be granted under the restricted share unit scheme of the Company adopted by the Board on February 2, 2021 with the value of the underlying shares on the date of grant being US$60,000. Such remuneration (i) has been recommended by the remuneration committee of the Company and proposed by the Board with reference to, among other things, (a) his duties and responsibilities within the Company; (b) the prevailing market conditions; and (c) the continuous expansion of the business scale and continuously heightening requirements on corporate governance of the Company over recent years, and (ii) is also subject to the approval of the Shareholders at the AGM.

Save as disclosed above, Dr. Sidransky (i) does not have any interests in the Shares within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); (ii) has not held any other positions with the Company or other members of the Group; (iii) has not been a director of any public company, the securities of which are listed on any securities market in Hong Kong or overseas, in the last three years; (iv) does not have any other major appointments and professional qualifications; (v) does not have any relationship with any Director, senior management or substantial or controlling shareholders of the Company; (vi) has no other information that needs to be disclosed pursuant to paragraphs (h) to (v) of Rule 13.51(2) of the Rules Governing the Listing of Securities of The Stock Exchange of Hong Kong Limited; and (vii) has no other matter that needs to be brought to the attention of the Shareholders.

The Board would like to take this opportunity to welcome Dr. Sidransky for joining the Board.

GENERAL

The circular of the AGM containing, among other things, (i) further details of the proposed re-election of Dr. Sidransky; (ii) the proposed remuneration for Dr. Sidransky; and (iii) the notice convening the AGM, will be despatched to the Shareholders in due course.

By order of the Board

Ascentage Pharma Group International

Dr. Yang Dajun

Chairman and Executive Director

Suzhou, People's Republic of China, March 31, 2021

As at the date of this announcement, the Board comprises Dr. Yang Dajun as Chairman and executive Director, Dr. Wang Shaomeng, Dr. Tian Yuan, Dr. Lu Simon Dazhong and Mr. Liu Qian as non-executive Directors, and Mr. Ye Changqing, Dr. Yin Zheng, Mr. Ren Wei and Dr. David Sidransky as independent non- executive Directors.

- 3 -